David J Wooten
Overview
Explore the profile of David J Wooten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Murillas I, Cutts R, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(3):493-502.
PMID: 39424680
Purpose: Detection of molecular residual disease (MRD) allows for the identification of breast cancer patients at high-risk of recurrence, with the potential that early initiation of treatment at early stages...
2.
Wooten D, Sinha I, Sinha R
Biomedicines
. 2022 Jan;
10(1).
PMID: 35052828
Survival rate for pancreatic cancer remains poor and newer treatments are urgently required. Selenium, an essential trace element, offers protection against several cancer types and has not been explored much...
3.
Wooten D, Meyer C, Lubbock A, Quaranta V, Lopez C
Nat Commun
. 2021 Jul;
12(1):4607.
PMID: 34326325
Drug combination discovery depends on reliable synergy metrics but no consensus exists on the correct synergy criterion to characterize combined interactions. The fragmented state of the field confounds analysis, impedes...
4.
Wooten D, Gebru M, Wang H, Albert R
J Pers Med
. 2021 Apr;
11(3).
PMID: 33799721
-mutant acute myeloid leukemia (AML) is an aggressive form of leukemia with poor prognosis. Treatment with inhibitors frequently produces a clinical response, but the disease nevertheless often recurs. Recent studies...
5.
Wooten D, Gomez Tejeda Zanudo J, Murrugarra D, Perry A, Dongari-Bagtzoglou A, Laubenbacher R, et al.
PLoS Comput Biol
. 2021 Mar;
17(3):e1008690.
PMID: 33780439
Candida albicans, an opportunistic fungal pathogen, is a significant cause of human infections, particularly in immunocompromised individuals. Phenotypic plasticity between two morphological phenotypes, yeast and hyphae, is a key mechanism...
6.
Wooten D, Albert R
Bioinformatics
. 2020 Sep;
37(10):1473-1474.
PMID: 32960970
Summary: Combinations of multiple pharmacological agents can achieve a substantial benefit over treatment with single agents alone. Combinations that achieve 'more than the sum of their parts' are called synergistic....
7.
Meyer C, Wooten D, Lopez C, Quaranta V
Trends Pharmacol Sci
. 2020 Mar;
41(4):266-280.
PMID: 32113653
Even as the clinical impact of drug combinations continues to accelerate, no consensus on how to quantify drug synergy has emerged. Rather, surveying the landscape of drug synergy reveals the...
8.
Wooten D, Groves S, Tyson D, Liu Q, Lim J, Albert R, et al.
PLoS Comput Biol
. 2019 Nov;
15(10):e1007343.
PMID: 31671086
Adopting a systems approach, we devise a general workflow to define actionable subtypes in human cancers. Applied to small cell lung cancer (SCLC), the workflow identifies four subtypes based on...
9.
Udyavar A, Wooten D, Hoeksema M, Bansal M, Califano A, Estrada L, et al.
Cancer Res
. 2019 Mar;
79(5):1014.
PMID: 30824677
No abstract available.
10.
Meyer C, Wooten D, Paudel B, Bauer J, Hardeman K, Westover D, et al.
Cell Syst
. 2019 Feb;
8(2):97-108.e16.
PMID: 30797775
Two goals motivate treating diseases with drug combinations: reduce off-target toxicity by minimizing doses (synergistic potency) and improve outcomes by escalating effect (synergistic efficacy). Established drug synergy frameworks obscure such...